Biohaven Pharma earnings missed by $0.39, revenue was in line with estimates

  • Investing.com
Biohaven Pharma earnings missed by $0.39, revenue was in line with estimates
Credit: © Reuters.

Investing.com - Biohaven Pharma (NYSE: BHVN ) reported fourth quarter EPS of $-1.81, $0.39 worse than the analyst estimate of $-1.42. Revenue for the quarter came in at $0.00 versus the consensus estimate of $0.00.

Biohaven Pharma's stock price closed at $48.02. It is up 42.66% in the last 3 months and up 233.47% in the last 12 months.

Biohaven Pharma saw positive EPS revisions and negative EPS revisions in the last 90 days. See Biohaven Pharma's stock price’s past reactions to earnings here.

According to InvestingPro, Biohaven Pharma's Financial Health score is "fair performance".

Check out Biohaven Pharma's recent earnings performance , and Biohaven Pharma's financials here.

Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar

Drop an image here or Supported formats: *.jpg, *.png, *.gif up to 5mb

Error: File type not supported

Drop an image here or

100